Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial

Адаптивная глубокая стимуляция мозга для динамического контроля походки при болезни Паркинсона: рандомизированное исследование целесообразности
Doris D. Wang, Philip A. Starr, Kenneth H. Louie, Hamid Fekri Azgomi, Jannine P. Balakid, Jessica E. Bath, 송성미, Jacob H. Marks, Julia T. Choi, Seongmi Song, Seongmi Song
2026-06-15

adaptive deep brain stimulationgait-phase biomarkersgait-synchronized stimulationpallidal DBSrandomized crossover trial
A randomized crossover study of five patients with Parkinson's disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS). Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase. We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle implantation were enrolled. We successfully identified personalized gait-phase biomarkers from cortical or pallidal field potentials in all five patients and embedded them into a bidirectional neurostimulator. During acute in-clinic testing, aDBS improved step variability and step symmetry versus cDBS. Three participants subsequently completed a double-blinded, multi-day crossover phase. In this setting, aDBS maintained general motor symptom control, reduced falls and yielded patient-specific gait improvements. No adverse events occurred and aDBS was well tolerated. These findings establish the feasibility of biomarker-driven, movement-synchronized neuromodulation and support the development of a larger randomized trial to determine clinical efficacy. ClinicalTrial.gov registration: NCT04675398 .
1
During acute in-clinic testing, aDBS improved step variability and step symmetry compared with continuous DBS (cDBS).
2
Gait-synchronized adaptive deep brain stimulation (aDBS) is feasible and safe in Parkinson’s disease patients.
3
Identified biomarkers were embedded into a bidirectional neurostimulator to drive gait-phase–synchronized aDBS.
4
In a double-blinded, multi-day crossover phase, aDBS maintained general motor symptom control while reducing falls.
5
Personalized gait-phase biomarkers were successfully identified from cortical or pallidal field potentials in all five participants.
6
Results support feasibility of biomarker-driven, movement-synchronized neuromodulation and justify a larger randomized trial.
7
aDBS yielded patient-specific gait improvements and was well tolerated with no adverse events reported.

Gait-synchronized adaptive deep brain stimulation system applied to patients with Parkinson’s disease (pallidal DBS with subdural cortical/pallidal field-potential biomarkers)

Feasibility, safety, and effects on gait control (step variability, step symmetry) and fall reduction when using patient-specific gait-phase biomarkers to drive movement-synchronized aDBS compared with continuous DBS

Publication Details
Publication Date
2026-06-15
Journal
Publisher
ISSN
Cited by
21
Access Type
Author Information
Authors
Doris D. Wang
Philip A. Starr
Kenneth H. Louie
Hamid Fekri Azgomi
Jannine P. Balakid
Jessica E. Bath
송성미
Jacob H. Marks
Julia T. Choi
Seongmi Song
Seongmi Song
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%